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OBJECTIVES: To present the clinical features and outcomes of outpatients who suffer from refractory ascites.
METHODS: This prospective observational study consecutively enrolled patients with cirrhotic ascites who
submitted to a clinical evaluation, a sodium restriction diet, biochemical blood tests, 24 hour urine tests and an
ascitic fluid analysis. All patients received a multidisciplinary evaluation and diuretic treatment. Patients who
did not respond to the diuretic treatment were controlled by therapeutic serial paracentesis, and a transjugular
intrahepatic portosystemic shunt was indicated for patients who required therapeutic serial paracentesis up to
twice a month.
RESULTS: The most common etiology of cirrhosis in both groups was alcoholism [49 refractory (R) and 11 non-
refractory ascites (NR)]. The majority of patients in the refractory group had Child-Pugh class B cirrhosis
(p=0.034). The nutritional assessment showed protein-energy malnutrition in 81.6% of the patients in the
R group and 35.5% of the patients in the NR group, while hepatic encephalopathy, hernia, spontaneous
bacterial peritonitis, upper digestive hemorrhage and type 2 hepatorenal syndrome were present in 51%,
44.9%, 38.8%, 38.8% and 26.5% of the patients in the R group and 9.1%, 18.2%, 0%, 0% and 0% of the
patients in the NR group, respectively (p=0.016, p=0.173, p=0.012, p=0.012, and p=0.100, respectively). Mortality
occurred in 28.6% of the patients in the R group and in 9.1% of the patients in the NR group (p=0.262).
CONCLUSION: Patients with refractory ascites were malnourished, suffered from hernias, had a high prevalence
of complications and had a high postoperative death frequency, which was mostly due to infectious processes.
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’ INTRODUCTION
Ascites is one of the most frequent complications of liver
cirrhosis and occurs in approximately 50% of patients with
compensated liver disease during an observation period of
approximately 10 years (1).
The development of ascites is associated with a worse disease
prognosis, and the estimated average life expectancy is
approximately two years for 50% of cirrhotic patients with
ascites and only approximately six months for those with a
urinary sodium excretion that is less than 10 mEq/L (2-4).
This condition is observed particularly in cirrhotic patients
with refractory ascites, which is thus indicative of the need
for definitive treatment with a liver transplantation. According
to the most-widely accepted pathophysiological hypothesis (5),
ascites occurs only in the presence of portal hypertension,
which leads to peripheral arterial vasodilatation and, con-
sequently, effective arterial hypovolemia. Ascites triggers the
activation of neurohumoral systems, the renin-angiotensin-
aldosterone system, and the sympathetic nervous system
(SNS); subsequently, ascites triggers the non-osmotic activa-
tion of antidiuretic hormone, which is a compensatory mech-
anism of organic homeostasis. These changes result in an
increased retention of salt and water. During the later stages
of cirrhosis, in addition to the maximal activation of neuro-
humoral systems, some patients will have an imbalance of
the intrarenal regulatory hormones, leading to hepatorenal
syndrome (6).
Depending on the duration of the underlying disease,
this cascade of pathophysiological changes may lead to
the development of ascites that can be easy or difficult to
mobilize; thus, treatment is not restricted to the typical forms
of therapy. In accordance with the most accepted pathophy-
siology, the typical treatment of ascites includes the restric-
tion of salt in the diet and, in most cases, a combination of
diuretics to obtain a satisfactory response, i.e., a negative
balance of salt and water and the disappearance of the ascites
and/or edema (7).
However, approximately 10% of patients with ascites will
have no resolution even when they adhere to a low sodium
diet (a maximum intake of 2.0 g salt/day, which is associated
with the use of diuretics). This group includes patients who
have an inability to mobilize ascites despite a confirmed
adherence to the dietary sodium restriction (88 mEq salt/day)DOI: 10.6061/clinics/2017(07)03
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and the administration of the maximum doses of oral diuretics,
such as 400 mg/day of spironolactone and 160 mg/day of
furosemide (refractory resistant); these patients may experi-
ence a rapid re-accumulation of fluid after the therapeutic
paracentesis despite their adherence to a sodium-restricted
diet or develop diuretic-related complications, such as progres-
sive azotemia, hepatic encephalopathy (HE), or progressive
electrolyte imbalances, which require the discontinuation of
the therapy (refractory intolerant) (8).
Thus, these patients are considered refractory to the con-
ventional treatment of ascites and should be subjected to
optional treatments, such as therapeutic serial paracentesis
(TSP) with albumin replacement and intravenous insertion
of a transjugular intrahepatic portosystemic shunt (TIPS);
LeVeen or Denver valve insertions may be suitable for
patients who are not eligible for TSP or TIPS. Moreover,
a liver transplantation should be considered in the absence of
contraindications (9,10).
Although this group of patients presents a poor clinical
situation, in most cases, they do not reach a sufficient score
on the Model for End-Stage Liver Disease (MELD) scoring
system to justify a liver transplantation, which increases the
risk of morbidity and mortality while awaiting definitive
treatment (2,10).
Considering this scientific perspective, the objectives of
this study were to present the clinical features and outcomes
of outpatients who suffer from refractory ascites.
’ METHODS
This observational study demonstrated our initial experi-
ence with such management at our institution and involved
patients with cirrhotic ascites who were enrolled consecu-
tively and prospectively and referred to the Clinic for
Refractory Ascites of the Division of Gastroenterology and
Hepatology – Hospital das Clínicas, University of São Paulo
School of Medicine, São Paulo, Brazil, between March
2009 and August 2010. Patients were excluded if they were
cirrhotic with ascites considered to have an easy resolution,
ascites of a different etiology, and ascites with concomitant
neoplasm or had current alcoholic hepatitis. Non-compliance
with the dietary restrictions, drug therapy and ascites
treatment guidelines was considered a cause of the false
refractoriness.
Patients were included only after undergoing a compre-
hensive clinical evaluation to confirm the refractory ascites,
which was based on their medical history, a physical exami-
nation and a plasma/ascitic fluid analysis (such as biochem-
istry, leucometry and culture). The patients participated in a
one-week orientation, during which a nutritionist focused on
the diuretic treatment withdrawal and the sodium restriction
diet; the orientation was followed by 24 hour urine tests to
quantify sodium and total proteins. Additional examinations
were usually performed, such as a chest X-ray, an electro-
cardiogram, an echocardiogram, an abdominal Doppler
ultrasound, an upper gastrointestinal endoscopy, and
arterial blood gases. The total count number and differential
leukocyte/mm3 ascites analyses were performed in all
patients who were subjected to the various paracenteses.
All patients were referred to a clinical multidisciplinary
evaluation with a cardiologist, nutritionist and psychologist.
The nutritional assessment was performed with anthropo-
metric parameters using the triceps skinfold (TSF) and mid-
arm muscle circumference (MAMC) according to procedures
performed in other studies (11,12). The TSF was measured
in mm using an appropriate caliper that was placed parallel
to the major axis of the non-dominant arm between the
acromion and the olecranon. The arm circumference (AC)
was measured in cm using a conventional measuring tape
without a clearance space that was placed at the midpoint
between the acromion and the olecranon on the non-
dominant arm during normal posture and relaxation.
The MAMC was measured in cm and was calculated
based on the AC. These parameters, including the estimation
of the percentage of depletion, were compared with the
normal range. The patients were then grouped into mild,
moderate and severe malnutrition groups based on these
comparisons (13). A nutritional assessment was performed,
and dietary guidance regarding sodium restriction and indi-
vidualized supplementation was provided as necessary.
The included patients then received the treatment protocol
and were evaluated weekly for the volume of the ascites,
body weight, renal function parameters, and electrolyte
dosages. If necessary, changes to their prescriptions or other
changes to the massive paracentesis with the intravenous
albumin replacement (8 g/liter of ascites removed) were
performed (13,14). In all outpatient care visits, the Child-
Pugh, MELD and MELD-Na scores were updated. All patients
were under hepatocellular carcinoma (HCC) surveillance
with abdominal ultrasound and alpha-fetoprotein.
The ascites treatment protocol initiated therapy in combi-
nation with a diuretic schedule, which was supplemented
with spironolactone (100 mg once daily) and furosemide
(40 mg once daily) in patients who showed an inefficiency
in weight loss after one week on the low sodium diet. Before
the start of the diuretic therapy, an evaluation of the renal
function parameters, urea, creatinine, and electrolytes, such
as sodium and potassium was performed, and the dosage
of sodium and potassium in the 24 hour urine test was
assessed (15). Patients returned for weekly reevaluation to
verify the effectiveness of the applied management and/or
the appearance of complications due to the use of diuretics.
In any of these events, the diuretic therapy had an optimized
dosage until it reached the maximum allowed or until the
administration was interrupted in the case of the onset of
complications, indicating the failure of this treatment modality
according to the criteria described for refractory ascites
(7,16). Diuretic-resistant ascites was defined according to the
International Ascites Club (7,8). In summary, at least one of
the following criteria is fulfilled in the absence of therapy
with a nonsteroidal anti-inflammatory drug:
 An inability to mobilize the ascites (manifested as
minimal to no weight loss) despite the confirmed adherence
to the dietary sodium restriction (88 mEq [2000 mg] per day)
and the administration of the maximum tolerable doses
of oral diuretics (400 mg of spironolactone and 160 mg of
furosemide once daily);
 Rapid re-accumulation of fluid after therapeutic para-
centesis despite adherence to a sodium-restricted diet; and
 The development of diuretic-related complications, such
as progressive azotemia, HE, or progressive electrolyte
imbalances.
Patients who were withdrawn from the conventional
treatment of ascites protocol were followed-up every two
weeks at most and were controlled by TSP with an intra-
venous albumin replacement. The insertion of TIPS was
indicated for those patients who were controlled by TSP,
required this procedure more than twice a month and did not
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present contraindications; even in patients with no urinary
sodium excretion, performing paracentesis every two weeks
controls the ascites (17). Currently, this form of therapy is
considered a secondary option in the treatment of refractory
ascites (7,9,18,19).
The patients with esophageal varices were treated accord-
ing to the Consensus of Variceal Bleeding of the Brazilian
Society of Hepatology (20) with an elastic bandage on the
medium and/or thick caliber veins with previous bleeding
or hematocystic spots, whose presence is associated with
beta-blocker drug treatments. The average blood pressure
of each patient, spontaneous bacterial peritonitis (SBP) back-
ground and previous or current renal failure were consid-
ered. In selected cases, the treatment was exclusively an
endoscopic treatment of the varicose veins.
The follow-up was performed from the date on which
the refractory ascites was diagnosed in each patient to the
closure of the study date (August 2010). The evaluation
period ranged from 3 to 17 months.
Ethics
The study protocol was approved by the Ethics Committee
of the Hospital das Clínicas, University of São Paulo School
of Medicine and conformed with the ethical guidelines of the
1975 Declaration of Helsinki (6th revision, 2008). Because this
is an observational study, the ethics committee waived the
requirement of informed consent from each patient included
in the study.
Statistical Analysis
For the qualitative variables, comparisons between the two
groups were performed using the chi-square test and Fisher’s
exact test. This study adopted the 5% level of significance,
and analysis of variance (ANOVA) was used for all statistical
calculations.
’ RESULTS
During the study period, 60 patients were enrolled as follows:
49 refractory ascites patients (R) and 11 non-refractory ascites
patients (NR).
The most common etiology of the cirrhosis in both the
refractory and non-refractory groups was alcoholism. The
average age was 57.5±8.8 years in the R group and 50.3±
8.1 years in the NR group (p=0.010), and males were pre-
dominant in both groups (72.9% in the R group and 66.7% in
the NR group; p=0.712) (Table 1).
The nutritional assessment showed a protein-energy mal-
nutrition in 81.6% of the patients in the R group and 35.5% of
the patients in the NR group (Table 2). HE, hernia, SBP and
hepatorenal syndrome (HRS) type 2 were present in 51%,
44.9%, 38.8% and 26.5%, respectively, of the patients in the
refractory ascites group and 9.1%, 18.2%, 0% and 0%, res-
pectively, of the patients in the non-refractory ascites group
(p=0.016, p=0.173, p=0.012 and p=0.100, respectively).
Of the 49 refractory patients, only 5 underwent the inser-
tion of TIPS. TIPS were inserted in patients who lost control
of the ascites by paracentesis or if this procedure had to be
performed twice a month without any absolute contra-
indications for TIPS. Although some patients needed three or
more paracenteses per month, several criteria contraindi-
cated the placement of TIPS. Although we had patients with
MELD scores o18 and Child-Pugh Class B, some patients
had persistent encephalopathies and/or grade42, HRS type
2 and/or other changes to the procedure that contraindicated
or would be controversial to its effectiveness. In total, 12
(24.49%) patients in the refractory group and 1 patient in the
non-refractory group required hospitalization during the
evaluation period. The causes of admission varied, including
decompensated ascites preventing the insertion of TIPS (5),
severe gastrointestinal bleeding (1), infection (3), and HE (3).
Five TIPS were inserted, but 4/5 (80%) patients presented
HE and required diuretics to control the ascites; 3/5 (60%)
patients who received TIPS required low doses of diuretics to
control the ascites. Furthermore, despite the use of diuretics
at tolerated doses, 1/5 (20%) patients returned to controlling
the ascites by serial paracentesis because of TIPS obstruction
30 days after the insertion, and this patient presented with a
worsening clinical condition and died on the 4th month after
the TIPS insertion due to an acute myocardial infarction.
Of the total number of enrolled patients, 6 patients (54.54%)
in the non-refractory group and 20 patients (40.81%) in the
refractory group received propranolol for more than 30 days as
a primary or secondary bleeding prophylaxis from gastro-
esophageal varices.
Mortality occurred in 28.6% of the patients in the R group
and 9.1% of patients in the NR group (p=0.262). The results of
the clinical complications diagnosed in both groups are
shown in Table 3. Of the 15 total deaths, 5 patients were post
liver transplantation, and 10 patients were on the waiting list
for transplantation. According to the total deaths, 14 were
in the refractory group; 9/14 patients were on the liver
transplantation list; 3/9 deaths were caused by umbilical
hernia rupture; and 2/9 deaths were caused by SBP, one of
Table 1 - Clinical Results.
Parameters R (49) NR (11) p-value
Age 57.5±8.8 49.9±7.9 0.010
Male gender (%) 73.5 63.6 0.712
Child-Pugh B (%) 71.4 36.4 0.034
MELD ± SD 13.4±4.2 11.2±4.0 0.126
MELD-Na ± SD 16.1±5.1 12.8±5.1 0.054
Table 2 - Nutritional Status.
Nutritional Evaluation R NR Total
Normal weight 4 (8.2%) 4 (36.4%) 8 (13.3%)
Mild malnutrition 7 (14.3%) 2 (18.2%) 9 (15.0%)
Moderate malnutrition 22 (44.9%) 2 (18.2%) 24 (40%)
Severe malnutrition 11 (22.4%) 1 (9.1%) 12 (20%)
Overweight 2 (4.1%) 1 (9.1%) 3 (5.0%)
Obese 3 (6.1%) 1 (9.1%) 4 (6.7%)
Table 3 - Results of Clinical Complications.
Clinical complications R (49) NR (11) p
HRS type 2 13 (26.5%) 0 0.100
HE 25 (51.0%) 1 (9.1%) 0.016
Hernias 22 (44.9%) 2 (18.2%) 0.173
SBP 19 (38.8%) 0 0.012
Hydrothorax 11 (22.4%) 1 (9.1%) 0.435
UDH 19 (38.8%) 0 0.012
Transplantation 9 (18.4%) 0 0.189
Mortality rate 14 (28.6%) 1 (9.1%) 0.262
Legend: HRS type 2: hepatorenal syndrome type 2; HE: hepatic
encephalopathy; SBP: spontaneous bacterial peritonitis; UDH: upper
digestive hemorrhage.
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which progressed to sepsis, and the other progressed to HRS.
In the other four cases (4/9), 3/9 deaths were not directly
related to the presence of the ascites (rather, they were
related to acute arterial thrombosis of the lower limbs, upper
gastrointestinal bleeding and pulmonary embolism), and the
other died due to cachexia in the course of the refractory
ascites with contraindications to liver transplantation, TIPS
and paracentesis. Five of the 14 deaths occurred post liver
transplantation, and three of these occurred due to infectious
complications. During this study, there were no cases with
HCC since it was an exclusion criterion. SBP occurred in two
cases (4.08%) of refractory patients.
’ DISCUSSION
The treatment of ascites in liver cirrhosis is typically per-
formed by different medical specialists. However, profes-
sionals other than gastroenterologists and hepatologists can
also perform the treatment procedures, including gastro-
enterological surgeons, nephrologists and infectologists.
Different medical doctors follow these patients depending on
their degree of familiarity with ascites treatment, and they
play a key role in the ultimate goal of therapy. However,
many professionals do not follow any established treat-
ment protocol, which may lead to the emergence of several
complications, such as HE and renal dysfunction, which are
the most frequent complications (7).
Because many physicians note difficulties in managing
massive ascites, we aimed to introduce a protocol that
identifies outpatient cirrhotic patients with ascites that is
considered difficult to manage (due to cirrhosis decompen-
sation). The patients were followed-up with nutritional
assessments to verify their adherence to the diet guidelines
according to their individual needs because there is a direct
relationship between malnutrition and increasing complica-
tions in cirrhotic patients with refractory ascites. Nutritional
parameters, such as body mass index and percentage of ideal
weight, have limitations in chronic liver disease mainly because
of fluid retention, which is often exhibited by patients,
including those without detectable ascites (21).
According to our results, 80% of the patients had some
degree of malnutrition in the initial evaluation, which was
frequently related to moderate or advanced cirrhosis. This
was also the profile of our patients, and the majority of
them were classified as Child-Pugh B (22,23); our results are
consistent with results of other studies (24). In several
studies, protein and calorie malnutrition have been asso-
ciated with an increased number of serious complications,
including ascites, variceal bleeding, increased surgical mor-
bidity and mortality, and reduced survival (25,26). This fact
is very important considering the results obtained in a recent
study (27), which showed that better nutritional support for
patients with refractory ascites led to lower rates of morbidity
and mortality compared with patients with refractory ascites
who did not have nutritional supplementation (23).
Thus, after excluding the other causes of ascites, which
were not related to liver cirrhosis and/or associated with
malignancies, the patients followed the treatment protocol
for ascites and always paid attention to the exclusion of
causes of false refractoriness (28-31).
Interestingly, among the complications presented during
the treatment in our refractory patients, upper digestive
hemorrhage (UDH), SBP, HE, HRS type 2, and umbilical
and/or inguinal-scrotal hernia were the most prevalent
complications and occurred in 38.8%, 38.8%, 51%, 26.5%,
and 44.9% of the patients, respectively. According to the
pathophysiology of ascites, the appearance of HRS type 2 is
one of the expected complications in advanced stage cirrhotic
patients with ascites, when the activation of the neuro-
humoral system, renin-angiotensin-aldosterone, SNS, and
antidiuretic hormone (ADH) are extreme and can no longer
return the balance of the hemodynamic parameters to
normal levels of blood pressure.
Thus, in some patients, there will be an increased activa-
tion of vasodilator hormones or a moderate production
of vasoconstrictors in the kidney, which often reduces the
effect of systemic and renal vasoconstriction but elicits a
renal failure that is stable for months. This renal failure is
likely to develop into a more serious impairment, depending
on external aggravating factors that are related to the pre-
sence of an acute circulatory dysfunction as it occurs, for
example, during the onset of SBP (8, 21). During the advanced
stage of cirrhosis, patients may not respond to the conven-
tional treatment with diuretics, and several complications
arising from its use can be diagnosed.
In addition, the patients frequently present asthenia,
anorexia, malnutrition, hernias, HE, SBP and renal dysfunc-
tion. Thus, our results described findings that are related to
severe cirrhotic patients with refractory ascites (22).
Although there were more patients with HRS and hernias
in the refractory ascites group, no significant difference was
observed in the frequency of these complications, which is
likely due to the small number of patients included in the
study. However, according to our results and the results of
others, even in this condition, this group of patients did not
achieve a MELD score that prioritizes liver transplantation,
which is of main importance since this may have been
related to the high percentage of deaths in the patients
waiting for liver transplantation (23, 24). The MELD-Na
appears to be a valid method to more readily benefit these
patients (25, 26, 32).
We emphasize that refractory ascites patients are extre-
mely and seriously ill (end-stage of liver disease). However,
these patients do not need to reach a certain MELD score to
be competitive with other cirrhotic patients on the liver
transplantation list. In addition, only some patients obtain
a score due to a special situation. Occasionally, the MELD
score increases due to the absence of major coagulation
disorders or a low alteration in the serum bilirubin level.
Therefore, it is important to emphasize that the MELD-Na
score could help hyponatremic patients with a worse pro-
gnosis, but it is not currently available. Thus, these patients
progressively evolve with renal dysfunction and recurrent
infections and may die before liver transplantation.
It is highly important to frequently diagnose the presence
of hernias in the patients with abdominal distensions due
to ascites since hernias were found to be a significant cause of
death in the group waiting for liver transplantation. Compli-
cations of spontaneous perforations led to discussions
regarding whether these patients would benefit from elective
surgery for the hernias, particularly for those who presented
with thinner and/or eroded skin (27, 33, 34).
Although five TIPS were inserted in the refractory patient
group in accordance with the inclusion criteria for this type
of therapy (9, 10, 18), we found that four of these patients
developed HE, either grade 1 or 2, which was easily resolved
and required diuretics at lower doses to control the ascites.
We also emphasize that at the time of this study, the released
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TIPS were not covered, increasing the possibility of dysfunc-
tion and clinical complications (35). Several reports in the
literature show the benefits of TIPS in controlling ascites
compared to serial voluminous paracentesis (36-38). TIPS
was performed in refractory ascites patients who underwent
more than two paracenteses each month for ascites control.
This frequency shows a loss of ascites control by paracentesis
and highlights a poor life quality and malnutrition in this
group of patients (39).
Our results are consistent with those reported in the
literature; in five meta-analysis studies, the insertion of TIPS
was shown to control ascites better than serial paracentesis
therapies but leads to a higher incidence of HE (3, 40-44).
This finding was highlighted in the EASL guidelines, which
described that the reported management of ascites resulted
more frequently in HE in the TIPS group compared to
the paracentesis group (45). More recently, a retrospective
study evaluating 70 covered TIPS and 80 serial paracent-
eses for refractory ascites treatment concluded that covered
"stents" improved the survival to medium- and long-term
without a significant increase in the short-term mortality
of patients with refractory ascites in clinical treatment
failure (46).
None of our clinical cases were consistent with post-
paracentesis circulatory dysfunction, but this finding was not
an aim of this study.
Regarding the frequency of deaths in our refractory
patients, complicated hernias were the most frequent causes
of death before transplantation, and bacterial infection was
an important cause of death post liver transplantation, which
was likely due to the advanced stage of the underlying
disease and the degree of malnutrition (23, 47-49).
Among the refractory patients who died pre-transplantation,
4/9 (44.4%) were taking propranolol, and no cause of death
was directly related to the refractory ascites; however, among
the refractory deaths after transplantation, 2/5 (40%) had
histories of propranolol use, and sepsis was the cause death.
In the non-refractory group, one patient who received beta-
blockers died due to SBP that progressed to sepsis. However,
the sample presented was small.
In conclusion, patients with refractory ascites were very
malnourished, frequently suffered from hernias and had a
high prevalence of renal dysfunction, SBP, upper gastro-
intestinal hemorrhage, and episodes of HE. Moreover, when
the patients reached a score eligible for liver transplantation,
they had a high frequency of postoperative death mostly
due to infectious processes. Thus, the developmental profile
of refractory patients based on our results shows the necessity
of reviewing the current criteria to prioritize liver transplan-
tation and minimize the high morbidity and mortality in this
group of patients. However, further studies with larger
numbers of patients are needed to confirm these data.
’ ACKNOWLEDGMENTS
Alves de Queiroz Family Fund for Research.
’ AUTHOR CONTRIBUTIONS
Caly WR and Ono SK conceived and designed the study. Caly WR, Abreu
RM, Bitelman B, Carrilho FJ and Ono SK performed the study, analyzed
the data, were responsible for the reagents/materials/analysis tools, provided
clinical data regarding the patients and critical advice on writing the manu-
cript. Abreu RM, Caly WR and Ono SK wrote the manuscript. Caly WR,
Bitelman B, Carrilho FJ and Ono SK provided clinical data regarding the
patients.
’ REFERENCES
1. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Com-
pensated cirrhosis: natural history and prognostic factors. Hepatology.
1987;7(1):122-8, http://dx.doi.org/10.1002/hep.1840070124.
2. Arroyo V, Bosch J, Gaya-Beltrán J, Kravetz D, Estrada L, Rivera F, et al.
Plasma renin activity and urinary sodium excretion as prognostic indi-
cators in nonazotemic cirrhosis with ascites. Ann Intern Med. 1981;94(2):
198-201, http://dx.doi.org/10.7326/0003-4819-94-2-198.
3. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal
AJ, et al. Persistent ascites and low serum sodium identify patients with
cirrhosis and low MELD scores who are at high risk for early death.
Hepatology. 2004;40(4):802-10, http://dx.doi.org/10.1002/hep.1840400409.
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J.
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of
renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151-7,
http://dx.doi.org/10.1002/hep.1840080532.
5. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Pérez-Ayuso RM, et al.
Sympathetic nervous activity, renin-angiotensin system and renal excre-
tion of prostaglandin E2 in cirrhosis. Relationship to functional renal
failure and sodium and water excretion. Eur J Clin Invest. 1983;13(3):271-8,
http://dx.doi.org/10.1111/j.1365-2362.1983.tb00100.x.
6. Runyon BA, AASLD Practice Guidelines Committee. Management of
adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;
49(6):2087-107, http://dx.doi.org/10.1002/hep.22853.
7. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal
syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):
164-76, http://dx.doi.org/10.1002/hep.510230122.
8. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al.
The management of ascites in cirrhosis: report on the consensus con-
ference of the International Ascites Club. Hepatology. 2003;38(1):258-66,
http://dx.doi.org/10.1053/jhep.2003.50315.
9. Senousy BE, Draganov PV. Evaluation and management of patients with
refractory ascites. World J Gastroenterol. 2009;15(1):67-80, http://dx.doi.
org/10.3748/wjg.15.67.
10. Salerno F, Badalamenti S, Incerti P, Tempini S, Restelli B, Bruno S, et al.
Repeated paracentesis and i.v. albumin infusion to treat ‘tense’ ascites in
cirrhotic patients. A safe alternative therapy. J Hepatol. 1987;5(1):102-8,
http://dx.doi.org/10.1016/S0168-8278(87)80067-3.
11. Merli M. Nutrient utilization in liver cirrhosis: what impact on nutritional
status? Nutrition. 1994;10(6):566-7.
12. Loguercio C, Sava E, Marmo R, del Vecchio Blanco C, Coltorti M.
Malnutrition in cirrhotic patients: anthropometric measurements as a
method of assessing nutritional status. Br J Clin Pract. 1990;44(3):98-101.
13. Blackburn GL, Thornton PA. Nutritional assessment of the hospitalized
patient. Med Clin North Am. 1979;63(5):11103-15, http://dx.doi.org/
10.1016/S0025-7125(16)31663-7.
14. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E,
Abecasis R, et al. Randomized trial comparing albumin, dextran 70,
and polygeline in cirrhotic patients with ascites treated by paracentesis.
Gastroenterology. 1996;111(4):1002-10, http://dx.doi.org/10.1016/S0016-
5085(96)70068-9.
15. Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, et al.
Spironolactone alone or in combination with furosemide in the treatment
of moderate ascites in nonazotemic cirrhosis. A randomized comparative
study of efficacy and safety. J Hepatol. 2003;39(2):187-92, http://dx.doi.
org/10.1016/S0168-8278(03)00188-0.
16. Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E,
et al. Combined versus sequential diuretic treatment of ascites in non-
azotaemic patients with cirrhosis: results of an open randomised clinical
trial. Gut. 2010;59(1):98-104, http://dx.doi.org/10.1136/gut.2008.176495.
17. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):
337-42, http://dx.doi.org/10.1056/NEJM199402033300508.
18. Boyer TD, Haskal ZJ,American Association for the Study of Liver
Diseases. The role of transjugular intrahepatic portosystemic shunt in the
management of portal hypertension. Hepatology. 2005;41(2):386-400,
http://dx.doi.org/10.1002/hep.20559.
19. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt for the
management of cirrhotic refractory ascites. Nat Clin Pract Gastroenterol
Hepatol. 2006;3(7):380-9, http://dx.doi.org/10.1038/ncpgasthep0523.
20. Bittencourt PL,Farias AQ,Strauss E,Mattos AA, Pannel of the 1st Brazilian
Consensus of Variceal Bleeding, Brazilian Society of Hepatology. Variceal
bleeding: consensus meeting report from the Brazilian Society of Hepa-
tology. Arq Gastroenterol. 2010;47(2):202-16, http://dx.doi.org/10.1590/
S0004-28032010000200017.
21. McCullough AJ, Mullen KD, Kalhan SC. Body cell mass and leucine
metabolism in cirrhosis. Gastroenterology. 1992;102(4 Pt 1):1325-33,
http://dx.doi.org/10.1016/0016-5085(92)70029-B.
409
CLINICS 2017;72(7):405-410 Refractory Ascites in Outpatients
Caly WR et al.
22. Müller MJ. Malnutrition in cirrhosis. J Hepatol. 1995;23 Suppl:31-5,
http://dx.doi.org/10.1111/j.1440-1746.2007.05222.x.
23. Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic
liver disease. Clin Liver Dis. 2014;18(1):179-90, http://dx.doi.org/10.1016/
j.cld.2013.09.004.
24. Teiusanu A, Andrei M, Arbanas T, Nicolaie T, Diculescu M. Nutritional
status in cirrhotic patients. Maedica (Buchar). 2012;7(4):284-9.
25. Altamirano J, Fagundes C, Dominguez M, García E, Michelena J,
Cárdenas A, et al. Acute kidney injury is an early predictor of mortality
for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;
10(1):65-71.e3, http://dx.doi.org/10.1016/j.cgh.2011.09.011.
26. Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indi-
cator of mortality among patients hospitalized with cirrhosis and portal
hypertension. Liver Int. 2009;29(9):1396-402, http://dx.doi.org/10.1111/
j.1478-3231.2009.02077.x.
27. Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, Perrella A, Perrella
O, et al. Preservation of nutritional-status in patients with refractory
ascites due to hepatic cirrhosis who are undergoing repeated paracentesis.
J Gastroenterol Hepatol. 2012;27(4):813-22, http://dx.doi.org/10.1111/
j.1440-1746.2011.07043.x.
28. Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P,
et al. Refractory ascites: pathogenesis, definition and therapy of a severe
complication in patients with cirrhosis. Liver Int. 2010;30(7):937-47,
http://dx.doi.org/10.1111/j.1478-3231.2010.02272.x.
29. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from
chronic liver disease: the importance of peripheral edema. Gastroenterology.
1986;90(6):1827-33, http://dx.doi.org/10.1016/0016-5085(86)90249-0.
30. Arroyo V, Ginés P, Rimola A, Gaya J. Renal function abnormalities,
prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in
cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J
Med. 1986;81(2B):104-22, http://dx.doi.org/10.1016/0002-9343(86)90912-5.
31. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E,
et al. Renal failure and bacterial infections in patients with cirrhosis:
epidemiology and clinical features. Hepatology. 2007;45(1):223-9,
http://dx.doi.org/10.1002/hep.21443.
32. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, preven-
tion and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):
1310-8.
33. Guevara M, Baccaro ME, Ríos J, Martín-Llahí M, Uriz J, Ruiz del Arbol L,
et al. Risk factors for hepatic encephalopathy in patients with cirrhosis
and refractory ascites: relevance of serum sodium concentration. Liver Int.
2010;30(8):1137-42, http://dx.doi.org/10.1111/j.1478-3231.2010.02293.x.
34. Andraus W, Pinheiro RS, Lai Q, Haddad LB, Nacif LS, D’Albuquerque
LA, et al. Abdominal wall hernia in cirrhotic patients: emergency
surgery results in higher morbidity and mortality. BMC Surg. 2015;15:65,
http://dx.doi.org/10.1186/s12893-015-0052-y.
35. Jung HS, Kalva SP, Greenfield AJ, Waltman AC, Walker TG, Athanasoulis
CA, et al. TIPS: comparison of shunt patency and clinical outcomes
between bare stents and expanded polytetrafluoroethylene stent-grafts.
J Vasc Interv Radiol. 2009;20(2):180-5, http://dx.doi.org/10.1016/j.jvir.
2008.11.005.
36. Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, et al.
A comparison of paracentesis and transjugular intrahepatic portosystemic
shunting in patients with ascites. N Engl J Med. 2000;342(23):1701-7,
http://dx.doi.org/10.1056/NEJM200006083422303.
37. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al.
The North American Study for the Treatment of Refractory Ascites.
Gastroenterology. 2003;124(3):634-41, http://dx.doi.org/10.1053/gast.2003.
50088.
38. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al.
Randomized controlled study of TIPS versus paracentesis plus albumin in
cirrhosis with severe ascites. Hepatology. 2004;40(3):629-35, http://dx.
doi.org/10.1002/hep.20364.
39. Runyon BA, AASLD. Introduction to the revised American Associa-
tion for the Study of Liver Diseases Practice Guideline management of
adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):
1651-3, http://dx.doi.org/10.1002/hep.26359.
40. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh
versus MELD. J Hepatol. 2005;42(42 Suppl 1):S100-7, http://dx.doi.org/
10.1136/gut.2006.107789.
41. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT,
et al. Hyponatremia and mortality among patients on the liver-transplant
waiting list. N Engl J Med. 2008;359(10):1018-26, http://dx.doi.org/
10.1056/NEJMoa0801209.
42. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA.
Serum sodium predicts mortality in patients listed for liver transplanta-
tion. Hepatology. 2005;41(1):32-9, http://dx.doi.org/10.1002/hep.20517.
43. Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa
M, et al. MELD score and serum sodium in the prediction of survival
of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56(9):
1283-90, http://dx.doi.org/10.1136/gut.2006.102764.
44. Marsman HA, Heisterkamp J, Halm JA, Tilanus HW, Metselaar HJ,
Kazemier G. Management in patients with liver cirrhosis and an umbilical
hernia. Surgery. 2007;142(3):372-5, http://dx.doi.org/10.1016/j.surg.2007.
05.006.
45. European Association for the Study of the Liver. EASL clinical practice
guidelines on the management of ascites, spontaneous bacterial perito-
nitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):
397-417, http://dx.doi.org/10.1016/j.jhep.2010.05.004.
46. Gaba RC, Parvinian A, Casadaban LC, Couture PM, Zivin SP, Lakhoo J,
et al. Survival benefit of TIPS versus serial paracentesis in patients
with refractory ascites: a single institution case-control propensity score
analysis. Clin Radiol. 2015;70(5):e51-7, http://dx.doi.org/10.1016/j.crad.
2015.02.002.
47. Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-
analysis of transjugular intrahepatic portosystemic shunt versus para-
centesis for refractory ascites. J Hepatol. 2005;43(6):990-6, http://dx.doi.
org/10.1016/j.jhep.2005.06.005.
48. Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, et al.
Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-
analysis. Liver Int. 2005;25(2):349-56, http://dx.doi.org/10.1111/j.1478-
3231.2005.01095.x.
49. D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered
transjugular intrahepatic portosystemic shunt for refractory ascites: a
meta-analysis. Gastroenterology. 2005;129(4):1282-93, http://dx.doi.org/
10.1053/j.gastro.2005.07.031.
410
Refractory Ascites in Outpatients
Caly WR et al.
CLINICS 2017;72(7):405-410
